Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€23.73

€23.73

0.810%
0.19
0.810%
€41.29

€41.29

 
26.04.24 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Latest predictions
16.04.24
-2.97%
buy
€42.30
15.04.24
-3.36%
buy
09.04.24
-3.50%
€41.73
01.04.24
-8.24%
buy
€30.00
21.03.24
-7.32%
buy
17.03.24
-7.32%
buy
Your prediction

Pfizer Inc. Stock

Pfizer Inc. gained 0.810% compared to yesterday.
The stock is one of the favorites of our community with 30 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 72.81% compared to the current price of 23.73 € for Pfizer Inc..
For the coming years our community has positive and negative things to say abot the Pfizer Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. 0.810% -2.727% -6.961% -32.311% -9.100% -25.859% -30.141%
Biogen Inc. 3.260% 7.014% -0.459% -25.172% -17.176% -12.343% -5.355%
Elanco Animal Health Inc. 2.540% 2.041% -15.545% 45.687% -8.299% -51.646% -
AbbVie Inc. -4.160% -4.443% -9.758% 1.814% 6.538% 61.993% 109.311%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.

*Pros: *

Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.

Comments

Prediction Buy
Perf. (%) -3.36%
Target price 42.305
Change
Ends at 15.04.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -8.24%
Target price 41.733
Change
Ends at 01.04.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.36%
Target price 41.513
Change
Ends at 01.03.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat
Show more

News

3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street: https://g.foolcdn.com/editorial/images/774353/solar-panels-with-engineers.jpg
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks

Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/773640/a-couple-looking-at-a-tablet-during-breakfast.jpg
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

"If you don't find a way to make money while you sleep, you will work until you die." That's a quote from billionaire investor Warren Buffett which emphasizes the importance of making your money

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia Bhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe